Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02291679 · ClinicalTrials.gov registry record · Phase 3
Trial of Linaclotide in Patients With Chronic Idiopathic Constipation
A Phase 3 study, sponsored by Ironwood Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,223
- Enrollment target
NCT02291679 is a Phase 3 study that has completed, run by Ironwood Pharmaceuticals. The registered enrollment target is 1,223 participants.
The verdict
NCT02291679, a Phase 3 study, has completed, sponsored by Ironwood Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,223 participants
- Enrollment target
Study Summary
The objective of this trial was to determine the efficacy and safety of linaclotide 72 ug administered once daily to patients with chronic idiopathic constipation (CIC). The primary efficacy parameter is the percentage of participants in each dosing group that meet the protocol definition for complete spontaneous bowel movement (CSBM) Overall Responder.
Interventions
- DRUG Matching Placebo
- DRUG Linaclotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,223 participants |
| Start Date | 2014-10 |
| Est. Completion | 2015-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02291679
The ClinicalTrials.gov registry entry for NCT02291679 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,223 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ironwood Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matching Placebo is the first listed.
NCT02291679 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02291679 about?
NCT02291679 is a clinical study titled "Trial of Linaclotide in Patients With Chronic Idiopathic Constipation". The objective of this trial was to determine the efficacy and safety of linaclotide 72 ug administered once daily to patients with chronic idiopathic constipation (CIC). The primary efficacy parameter is the percentage of participants in each dosing group that meet the protocol definition for comple...
What is the current status of trial NCT02291679?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,223 participants. The study started on 2014-10. Estimated completion is 2015-08.
What interventions are being tested in trial NCT02291679?
The interventions under investigation include: Matching Placebo (DRUG), Linaclotide (DRUG).
Who is sponsoring clinical trial NCT02291679?
This trial is sponsored by Ironwood Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.